

PRESS RELEASE
11 September 2023 15:30:00 CEST



Schelin Catheter® has had its premiere in France.

At the Centre Hospitalier du Pays d'Aix in Aix-en-Provence, Schelin Catheter has today had its premiere in France.

Dr. Marc Fourmarier today became the first in France to use the Schelin Catheter. Three patients undergoing water vapor therapy (Rezüm™, Boston Scientific Corporation) were given local anesthesia using ProstaLund's injection tools prior to the procedures.

Over the past year, Schelin Catheter has been used as an injection tool before a thousand prostate treatments, varying methods, around the world. The greatest experience has been before water vapor therapy and in almost all cases it has worked excellently to perform these treatments in local anesthesia thanks to ProstaLund's catheter. Today was the premiere in France where Dr. Fourmarier performed 3 Rezum treatment and was very pleased with the results provided by the Schelin Catheter. In the long term, this will enable him and the hospital to move the water vapor therapies from a resource-intensive operating room to a polyclinical setting.

In France, more than 80,000 active treatments of benign prostatic hyperplasia are performed per year.

Johan Wennerholm, CEO ProstaLund: "I am still happy but not surprised anymore, Schelin Catheter continues to make the urologists happy and impressed. What's interesting about France is that we're trying out a new sales concept, agency agreement. ProstaLund sells directly to the hospitals and "owns" the customer in a different way. In addition to better direct contact, this enables a better gross margin compared to going through a distributor. We will evaluate this Sales Channel with excitement."

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com



PRESS RELEASE
11 September 2023 15:30:00 CEST

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Attachments

Schelin Catheter® has had its premiere in France.